Skip to Content


In the US, Tasigna (nilotinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Chronic Myelogenous Leukemia.

US matches:

UK matches:

Ingredient matches for Tasigna


Nilotinib is reported as an ingredient of Tasigna in the following countries:

  • Bosnia & Herzegowina
  • China
  • Colombia
  • Cyprus
  • Finland
  • Greece
  • Hong Kong
  • Lebanon
  • Peru
  • Philippines
  • Singapore
  • Slovakia
  • Slovenia
  • Taiwan
  • Tunisia
  • Turkey
  • Vietnam

Nilotinib hydrochloride (a derivative of Nilotinib) is reported as an ingredient of Tasigna in the following countries:

  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Croatia (Hrvatska)
  • Czech Republic
  • Denmark
  • Egypt
  • Estonia
  • France
  • Georgia
  • Iceland
  • Indonesia
  • Ireland
  • Italy
  • Japan
  • Latvia
  • Lithuania
  • Macedonia
  • Netherlands
  • New Zealand
  • Norway
  • Oman
  • Poland
  • Romania
  • Russian Federation
  • Serbia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Thailand
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.